Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.
The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer.
Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors.
In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma.
The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies.
Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 26, 24 | -0.86 Increased by +39.44% | -0.99 Increased by +13.13% |
| Mar 14, 24 | -0.54 Increased by +8.47% | -0.96 Increased by +43.75% |
| Nov 8, 23 | -0.91 Decreased by -68.52% | -0.92 Increased by +1.09% |
| Aug 10, 23 | -0.82 Decreased by -121.75% | -0.97 Increased by +15.46% |
| May 11, 23 | -1.42 Decreased by -425.93% | -0.98 Decreased by -44.90% |
| Mar 9, 23 | -0.59 Increased by +20.27% | -0.66 Increased by +10.61% |
| Nov 14, 22 | -0.54 Decreased by -35.00% | -0.97 Increased by +44.33% |
| Aug 10, 22 | 3.77 Increased by +1.15 K% | 5.42 Decreased by -30.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -39.18 M Decreased by -57.42% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -32.21 M Decreased by -118.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -57.96 M Decreased by -349.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -27.09 M Increased by +16.69% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -24.89 M Decreased by -43.46% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 174.90 M Increased by +1.22 K% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -12.89 M Decreased by -18.32 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | -37.85 M Decreased by N/A% | -32.51 M Decreased by -14.70% | Increased by +85.90% Decreased by N/A% |